Freedom of information (FOI) releases from OUH

This is a disclosure log of Oxford University Hospitals NHS Foundation Trust's responses to freedom of information (FOI) or environmental information regulations (EIR) requests that might be of wider public interest.

If you can't find the information you're looking for, you can make a new FOI request.

Filters

Clear filters
  • Keywords filters

  • Year filters

  • Month filters

132 disclosures

  1. Please provide anonymised patient data on inpatient referrals to the JR endoscopy service for financial years 2024-25 and 2025-26:

    1) For referrals requested on weekends and bank holidays - demand by type (urgency) and when (by a Saturday, Sunday or a bank holiday) and

    2) performed endoscopies by type (urgency), and when completed (weekend/Bank holiday or week day and wait times in days

    Published: 14 September 2026

  2. Under the Freedom of Information Act 2000, please provide copies of emails, correspondence, meeting minutes, meeting papers and internal communications held by Oxford University Hospitals NHS Foundation Trust concerning the backlog or delays in hepatology consultant appointments or hepatology outpatient services.

    Please cover the period 1 January 2025 to the date of this request.

    I am particularly interested in communications discussing:

    1. The size and extent of the hepatology appointment backlog.
    2. The reasons for the backlog or delays.
    3. Concerns or risks arising from patients waiting for appointments.
    4. Complaints or concerns raised internally about the backlog.
    5. Discussions between hepatology consultants, clinical leads, managers and Trust executives.
    6. Communications with NHS England, the relevant ICB or other NHS organisations concerning the backlog.
    7. Actions proposed or taken to reduce the backlog, including additional clinics, consultant capacity, recruitment, outsourcing or other measures.
    8. Any recovery plans, targets or timescales for reducing the backlog.

    Published: 14 September 2026

  3. We are seeking recorded information relating to your Trust’s compliance with the statutory learning disability and autism training requirements for health and social care staff, introduced under the Health and Care Act 2022 and associated regulations, including the implementation of the Oliver McGowan Code of Practice.

    Please provide the following information for your Trust.

    1. Training programme used

    a) Please confirm whether the Trust uses:

    The Oliver McGowan Mandatory Training on Learning Disability and Autism; or

    An alternative training programme intended to meet the statutory requirements.

    b) If an alternative training programme is used, please provide:

    The name and description of the training programme(s);

    and

    Any recorded rationale, policy, or assessment used to determine that the alternative programme satisfies the statutory requirement.

    2. Workforce size

    Please provide the total number of staff employed by the Trust (headcount), using your standard reporting methodology, for each of the last three completed reporting years; and please state the reporting period used (e.g. calendar year, financial year). This should include temporary/bank/agency/locum staff.

    3. Training eligibility and compliance data

    For each of the last three completed reporting years (using your standard annual training compliance reporting cycle and stating the reporting period used), please provide:

    a) The total number of staff identified as requiring learning disability and autism training.

    b) If training is delivered at different levels/tiers, for each level/tier:

    The number of staff identified as requiring that level/tier;

    The number of staff recorded as being compliant with that level/tier;

    c) If training is only delivered at a single tier, please state number of staff recorded as being compliant with the training.

    d) The equivalent figures specifically for Psychiatrists and trainee Psychiatrists.

    4. Definitions and methodology

    Please provide definitions and methods used to compile the figures above, including:

    a) Your definition of “compliant” for reporting purposes, including whether this requires completion of all required components of the relevant training.

    b) Any internal guidance, policy, criteria, or role-mapping used to determine:

    Which staff are required to undertake the training;

    and

    Which staff are required to complete different levels/tiers (if applicable).

    5. Governance, reporting and audit

    Please provide copies of any recorded reports, audits, dashboards, committee papers, board reports, or submissions to external regulators from the last three completed reporting years related to monitoring, auditing, or reporting compliance with these training requirements.

    Published: 11 September 2026

  4. 1. What is the number of surgical procedures cancelled or postponed since Jan 1st 2022 due to problems with surgical instruments, including: inadequate sterilisation, missing instruments, faulty equipment, or contamination concerns?

    2. What is the number of internal incident reports or safety concerns raised since Jan 1st 2022 from health practitioners referring to issues with surgical equipment or instruments? Please break down the information by calendar year and hospitals in your trust.

    Published: 11 September 2026

  5. 1. Please tell me the longest time a patient spent in your emergency department (in days or hours) from arrival to departure (ie. when they were admitted, transferred or discharged) in each of the following years:
    a) 2026 to date
    b) 2025
    c) 2024

    2. For each case listed in question 1, please provide: -
    a) the approximate age and sex of the patient (or state whether they were an adult or a child)
    b) in brief, the reason for the wait

    3. Please tell me how many patients spent over seven days in your emergency department (ie. when they were admitted, transferred or discharged) in each of the following years:
    a) 2026 to date
    b) 2025
    c) 2024

    4. Please tell me how many patients spent over 31 days in your emergency department (ie. when they were admitted, transferred or discharged) in each of the following years:
    a) 2026 to date
    b) 2025
    c) 2024

    5. Please tell me the longest delayed discharge in your trust (in days or hours) for each of the following years: (by which I mean when someone remains in hospital despite being medically ready to leave)
    a) 2026 to date
    b) 2025
    c) 2024

    6. For each case listed in question 5, please provide: -
    a) the approximate age and sex of the patient (or state whether they were an adult or a child)
    b) in brief, the reason for the delay

    7. Please tell me how many delayed discharges there were in your trust which lasted longer than 31 days in each of the following years:
    a) 2026 to date
    b) 2025
    c) 2024

    8. Please tell me how many delayed discharges there were in your trust which lasted longer than 183 days in each of the following years:
    a) 2026 to date
    b) 2025
    c) 2024

    Published: 10 September 2026

  6. 1. I am writing to you to request any information on all emergency department attendances for patients under 18-years of age (up to 17 years and 11 months) that were found to have SVT. For each case, I am looking for:
    a. Age,
    b. gender,
    c. treatment provided,
    d. whether treatment was successful and if not what happened after,
    e. and arrival method (highlighting those who were conveyed by ambulance).

    If there is any other information that the clinical team feel would be helpful based on the information provided, I would be greatly appreciative of this.

    Published: 10 September 2026

    1. The number of patients currently receiving each long-term prophylactic medicine — lanadelumab, berotralstat, garadacimab, plasma-derived C1-esterase inhibitor (Cinryze and/or Haegarda) — as at the most recent month available.

    2. The same counts for each month/quarter from January 2023 onward, if readily held.

    3. A breakdown of the current counts by patients' ICB of residence (or first half of postcode / "out-of-area vs in-area"), to whatever level your systems allow without identifying individuals.

      For lanadelumab specifically, the split between every-2-week and every-4-week dosing among current patients, if recorded.

    Published: 10 September 2026

  7. 1. Please could you provide the following information in relation to the recruitment of the Interim Director of Transformation role:


    a. The dates the role was advertised via NHS Jobs (Trac Jobs)
    b. The total number of applicants who applied for the position.

    Published: 10 September 2026

  8. Please provide for each month from January 2016 to the most recent period for which data is available:

    1. The number of patients attending the trust's emergency departments with a primary diagnosis of:

    - Heatstroke
    - Heat exhaustion
    - Other heat-related illnesses or conditions

    2. The number of patients admitted to hospital following attendance with a heat-related illness

    3. The number of patients requiring intensive care treatment following a heat-related illness

    4. The number of deaths recorded where heatstroke or another heat-related illness was recorded as a primary or contributing factor, if held

    5. Any internal reports, assessments, briefings or analyses produced in 2026 regarding the impact of hot weather or heatwaves on patient demand, emergency department attendance, admissions, or hospital operations.

    Published: 10 September 2026

  9. Please could you answer the questions below in relation to the number of patients treated with these specific medicines from the 1st of April 2026 to the 30th of June 2026, or for the latest time-period you have data for. It would fantastic if you included data for all hospitals in your Trust.

    Q1. How many patients were treated with the following medicines in total regardless of diagnosis in the 3 months between the start of April 2026 to the end of June 2026, or latest 3-month period available? Name of monotherapy or combination Number patients treated

    1.1 Glofitamab (Columvi) monotherapy
    1.2 Glofitamab (Columvi) + Gemcitabine + Oxaliplatin (Glo + GEMOX)
    1.3 Epcoritamab (Tepkinly)
    1.4 Tafasitamab (Minjuvi)
    1.5 Lenalidomide
    1.6 Daratumumab (Darzalex)

    Q2. How many patients with a diagnosis of Follicular Lymphoma were treated with the following medicines, in the 3 months between the start of April 2026 to the end of June 2026, or latest 3-month period available? Name of monotherapy or combination Number patients treated

    2.1 Epcoritamab (Tepkinly) Monotherapy
    2.2 Epcoritamab (Tepkinly) + Rituximab + Lenalidomide (E + R2)
    2.3 Rituximab + Lenalidomide (R2)
    2.4 Tafasitamab (Minjuvi) + Rituximab + Lenalidomide (Tafa + R2)

    Q3. How many patients with a diagnosis of Multiple Myeloma were treated with the following medicines in the 3 months between the start of April 2026 to the end of June 2026, or latest 3-month period available? Name of medicine, combination or monotherapy Number patients treated

    3.1 Daratumumab + Bortezomib + Thalidomide + Dexamethasone (DVTD)
    3.2 Daratumumab + Lenalidomide + Dexamethasone (DRD)
    3.3 Daratumumab + Bortezomib + Dexamethasone (DVD)
    3.4 Daratumumab + Bortezomib + Lenalidomide + Dexamethasone (DVRD)
    3.5 Daratumumab Monotherapy
    3.6 Isatuximab + Bortezomib + Lenalidomide + Dexamethasone (IVRD) 3.7 Isatuximab + Pomalidomide + Dexamethasone (IPD)
    3.8 Isatuximab + Carfilzomib + Dexamethasone (IKD)
    3.9 Belantamab mafodotin Monotherapy
    3.10 Belantamab mafodotin + Bortezomib + Dexamethasone (BVD)
    3.11 Belantamab mafodotin + Pomalidomide + Dexamethasone (BPD)
    3.12 Lenalidomide + Dexamethasone (RD)
    3.13 Lenalidomide Maintenance Monotherapy

    Q4. How many patients with the following types of Myeloproliferative Disease were treated with the following medicines, in the 3 months between the start of April 2026 to the end of June 2026, or latest 3-month period available? Name of medicine All Types of Myeloproliferative Disease Myelofibrosis Polycythaemia Vera Essential Thrombocythaemia

    4.1 Fedratinib (Inrebic)
    4.2 Momelotinib (Omjjara)
    4.3 Peginterferon Alfa-2a (Pegasys)
    4.4 Ropeginterferon Alfa-2b (Besremi)
    4.5 Ruxolitinib (Jakavi)

    Published: 10 September 2026